Global E-Health Forum - Hamburg 2010

25-26 October 2010, Hamburg, Germany.
The Global E-Health Forum has been conceived to create a unique opportunity to discuss potential solutions in patient-centric health management. The past three Baltic Conferences on E-Health (2007-2009) have generated considerable interest in countries far beyond the Baltic Sea Region. The reason is simple: Healthcare systems all over the world are facing very similar challenges. Demographic shifts, increased burden of chronic diseases and expensive treatments as well as the impact of globalization - to mention some of the most important ones.

Therefore, organisers of Baltic Conference on E-Health have decided to found the "Global E-Health Forum". The Global E-Health Forum will replace the Baltic Conference on E-Health and is scheduled for following dates:

Global E-Health Forum - Hamburg 2010
25-26 October 2010.

Hosts of Global E-Health Forum 2010 are the European Health Telematics Association (EHTEL), the Hamburg Chamber of Commerce and IBM in cooperation with Asklepios.

Program Outline

  • October 25, 2010
    At the Hamburg Chamber of Commerce, you may expect presentations of keynote speakers from different continents, breakout sessions (workshops and as well as discussion forums) and an accompanying exhibition of solution providers. The first day will end with a reception in the U.S. Consulate General ("the little White House at the lake Alster").
  • October 26, 2010
    The program at Asklepios clinics will offer presentations, guided tours and show cases of solution providers and a panel discussion.

If you are interested in the sponsorship opportunities (platinum sponsor, premium sponsor and sponsor/workshop) or in exhibiting at the Global E-Health Forum on October 25 in the Hamburg Chamber of Commerce, please explore:

Register now to benefit from early bird fee of Euro 299 incl. VAT. Regular fee will be Euro 399 incl. VAT. The fee includes the admission to all conference sessions, lunches, coffee breaks and the evening reception on October 25.

For further information and registration, please visit:
http://www.global-ehealth-forum.com

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]